Healthcare / BiotechnologyNasdaqCM
$1.26
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF n/d · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
1/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$5M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-121.5%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-7.6M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Net Income | $-7.6M | $-7.6M | $-12.3M | $-7.8M | $-9.6M | $-7.9M | $-3.2M |
| EBITDA | — | — | — | — | — | $-7.9M | $-3.2M |
| EPS | -8.16 | -8.16 | -80.32 | -39.99 | -13.92 | -2.43 | -1.69 |
| Returns | |||||||
| ROE | -121.5% | -121.5% | -787.1% | -122.7% | -159.6% | -78.2% | 101.8% |
| Growth & Yield | |||||||
| EPS Growth | 89.8% | 89.8% | -100.9% | -187.3% | -472.8% | -43.8% | — |
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.